Evidence map›Paper›PMID 41029680›Full record

ReviewJournal of translational medicine2025

Extracellular vesicles for targeted drug delivery: advances in surface modification strategies and therapeutic applications.

Minghui Hu, Yuxin Han, Xin Zhang, Shengqian Tian, Zhenghui Shang, Zhixiang Yuan, Lili He

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Minghui HuSouthwest Minzu University, Chengdu, 610225, China.
Yuxin HanSouthwest Minzu University, Chengdu, 610225, China.
Xin ZhangSouthwest Minzu University, Chengdu, 610225, China.
Shengqian TianSouthwest Minzu University, Chengdu, 610225, China.
Zhenghui ShangYichang Central People's Hospital, Yichang, China.
Zhixiang YuanSouthwest Minzu University, Chengdu, 610225, China.
Lili HeSouthwest Minzu University, Chengdu, 610225, China. 21900048@swun.edu.cn.

Funding

Fundamental Research Funds for the Central Universities of Southwest Minzu University ZYN2025117Medical and Health Research Foundation from the Science and Technology Department of Yichang A24-2-030
6 · The paper itself

Abstract

Extracellular vesicles (EVs) refer to a heterogeneous group of cell-derived membrane structures originating from endosomes or plasma membranes. EVs can be used as excellent medication carriers due to their characteristic as natural carriers for bioactive substances. They can be employed for intercellular communication to transport bioactive lipids, proteins, RNAs, DNA, and peptide segments for releasing into the extracellular surroundings. This paper discusses the biological characteristics of EVs, current methodologies for their isolation and purification, with particular emphasis on emerging strategies for EVs surface engineering. The methods for surface modification can be categorized into two approaches: pre-isolation and post-isolation. Pre-isolation methods involve genetic manipulation or metabolic engineering of the source cells to alter the EVs surface, while post-isolation methods entail physical or chemical modifications after EVs have been isolated. Based on the modification methods mentioned above, we present how these modified EVs can be utilized to treat specific diseases, including brain disorders, tumors, and liver conditions.

Indexed as

Drug Delivery SystemsExtracellular VesiclesAnimalsHumansSurface PropertiesBiocarrier materialsExtracellular vesiclesSurface modificationTargeted delivery

Identifiers

PMID41029680
PMCPMC12486671

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.